{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:43:48Z","timestamp":1791607428292,"version":"4.3.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NSFC\/RGC and HKU seed fund for basic research","award":["17111421, 201910159222 and 104006152"],"award-info":[{"award-number":["17111421, 201910159222 and 104006152"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Rosacea is a chronic inflammatory skin disorder characterized by symptoms like itching, redness, and impaired skin barrier function. Mast cell activation plays a crucial role in its pathogenesis. Recent evidence shows higher expression of mast cell receptor MRGPRX2\/MRGPRB2 in rosacea patients\u2019 skin tissues and its potential as a novel drug target. We evaluated the therapeutic effect of a novel small-molecule MRGPRX2\/MRGPRB2 antagonist in a mouse model of rosacea and itch.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The therapeutic effects of GE1111 were evaluated in vivo on wildtype and MRGPRB2 knock-out mice with LL-37-induced rosacea. Serum MCP-1 level and histochemistry measured inflammation and mast cell degranulation in skin tissue. Functional in vitro cell culture assays were developed using MRGPRX2\/MRGPRB2 agonist LL-37, mast cells, keratinocytes, and macrophage cell lines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>LL-37-treated mice showed redness, increased serum MCP-1, and epidermal thickness of skin tissue, while these changes were absent in LL-37-treated MRGPRB2 knock-out mice. Treatment with GE1111 reduced rosacea symptoms, epidermal thickness, and serum MCP-1 levels. GE1111 protected tight junction protein expression and reduced mast cell degranulation and inflammatory cytokine gene and protein expression in skin lesions. GE1111 treatment reduced the number and duration of itch in the compound 48\/80 induced itch model. In vitro evidence showed GE1111\u2019s mechanism by inhibiting inflammatory interaction of mast cells with keratinocytes and macrophages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GE1111 showed promising therapeutic effects in rosacea via targeting interactions between mast cells, keratinocytes, and macrophages and inhibiting inflammatory cytokines. These findings open possibilities for developing MRGPRX2\/MRGPRB2 antagonists as novel treatments for rosacea.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00011-025-02144-y","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T12:21:18Z","timestamp":1764159678000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Therapeutic effect of an MRGPRX2\/MRGPRB2 antagonist on LL-37-induced rosacea-like inflammation in mice"],"prefix":"10.1007","volume":"74","author":[{"given":"Billy Kwok Chong","family":"Chow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye Gi","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaik Abdullah","family":"Nawabjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kesang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"issue":"6","key":"2144_CR1","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.jaad.2018.08.049","volume":"80","author":"AF Alexis","year":"2019","unstructured":"Alexis AF, et al. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: review and clinical practice experience. J Am Acad Dermatol. 2019;80(6):1722\u20139. e7.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2144_CR2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1067\/mjd.2002.120625","volume":"46","author":"J Wilkin","year":"2002","unstructured":"Wilkin J, et al. Standard classification of rosacea: report of the National rosacea society expert committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002;46(4):584\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2144_CR3","first-page":"282","volume":"179","author":"L Gether","year":"2018","unstructured":"Gether L, et al. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol. 2018;179(2):282\u20139.","journal-title":"Br J Dermatol"},{"issue":"4","key":"2144_CR4","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1365-2133.2011.10436.x","volume":"165","author":"M Augustin","year":"2011","unstructured":"Augustin M, et al. Prevalence of skin lesions and need for treatment in a cohort of 90 880 workers. Br J Dermatol. 2011;165(4):865\u201373.","journal-title":"Br J Dermatol"},{"key":"2144_CR5","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/jdv.20249","volume":"39","author":"M Kumar","year":"2024","unstructured":"Kumar M, et al. Beyond the classic players: mas-related G protein\u2010coupled receptor member X2 role in pruritus and skin diseases. J Eur Acad Derm Venereol. 2024;39:476.","journal-title":"J Eur Acad Derm Venereol"},{"issue":"4 Suppl 1","key":"2144_CR6","first-page":"S17","volume":"13","author":"SM Johnson","year":"2020","unstructured":"Johnson SM, Berg A, Barr C. Managing rosacea in the clinic: from pathophysiology to treatment\u2014a review of the literature. J Clin Aesthetic Dermatol. 2020;13(4 Suppl 1):S17.","journal-title":"J Clin Aesthetic Dermatol"},{"issue":"5","key":"2144_CR7","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.jid.2023.03.355","volume":"143","author":"Y Nakamura","year":"2023","unstructured":"Nakamura Y, et al. 350 increased LL37 in patients with psoriasis and rosacea promotes the uptake of low-density lipoprotein and development of atherosclerosis. J Invest Dermatol. 2023;143(5):S60.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"2144_CR8","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nm1616","volume":"13","author":"K Yamasaki","year":"2007","unstructured":"Yamasaki K, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13(8):975\u201380.","journal-title":"Nat Med"},{"issue":"5","key":"2144_CR9","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jaad.2014.08.028","volume":"72","author":"AM Two","year":"2015","unstructured":"Two AM, et al. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol. 2015;72(5):749\u201358.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2144_CR10","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/jid.2012.14","volume":"132","author":"KN Kanada","year":"2012","unstructured":"Kanada KN, Nakatsuji T, Gallo RL. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of Cathelicidin. J Invest Dermatol. 2012;132(5):1435\u201342.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"2144_CR11","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1016\/j.jid.2022.05.005","volume":"142","author":"S Roy","year":"2022","unstructured":"Roy S, et al. Role of MrgprB2 in Rosacea-Like inflammation in mice: modulation by \u03b2-Arrestin 2. J Invest Dermatol. 2022;142(11):2988\u201397. e3.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"2144_CR12","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1038\/jid.2014.222","volume":"134","author":"Y Muto","year":"2014","unstructured":"Muto Y, et al. Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea. J Invest Dermatol. 2014;134(11):2728\u201336.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2144_CR13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jdermsci.2018.12.004","volume":"93","author":"JE Choi","year":"2019","unstructured":"Choi JE, et al. Botulinum toxin blocks mast cells and prevents rosacea like inflammation. J Dermatol Sci. 2019;93(1):58\u201364.","journal-title":"J Dermatol Sci"},{"key":"2144_CR14","doi-asserted-by":"crossref","first-page":"153149","DOI":"10.1016\/j.phymed.2019.153149","volume":"68","author":"J Wang","year":"2020","unstructured":"Wang J, et al. Inhibitory function of Shikonin on MRGPRX2-mediated pseudo-allergic reactions induced by the secretagogue. Phytomedicine. 2020;68:153149.","journal-title":"Phytomedicine"},{"issue":"1","key":"2144_CR15","doi-asserted-by":"crossref","first-page":"11628","DOI":"10.1038\/s41598-018-29965-8","volume":"8","author":"A Navin\u00e9s-Ferrer","year":"2018","unstructured":"Navin\u00e9s-Ferrer A, et al. MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia. Sci Rep. 2018;8(1):11628.","journal-title":"Sci Rep"},{"issue":"5","key":"2144_CR16","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3390\/cells10051033","volume":"10","author":"M Kumar","year":"2021","unstructured":"Kumar M, Duraisamy K, Chow BKC. Unlocking the non-IgE-mediated pseudo-allergic reaction puzzle with mas-related G-protein coupled receptor member X2 (MRGPRX2). Cells. 2021;10(5):1033.","journal-title":"Cells"},{"key":"2144_CR17","doi-asserted-by":"crossref","first-page":"559589","DOI":"10.3389\/fimmu.2020.559589","volume":"11","author":"A Dondalska","year":"2020","unstructured":"Dondalska A, et al. Amelioration of compound 48\/80-mediated itch and LL-37-induced inflammation by a single-stranded oligonucleotide. Front Immunol. 2020;11:559589.","journal-title":"Front Immunol"},{"issue":"4","key":"2144_CR18","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaci.2022.12.805","volume":"151","author":"M Kumar","year":"2023","unstructured":"Kumar M, et al. Novel small molecule MRGPRX2 antagonists inhibit a murine model of allergic reaction. J Allergy Clin Immunol. 2023;151(4):1110\u201322.","journal-title":"J Allergy Clin Immunol"},{"key":"2144_CR19","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3389\/fimmu.2020.00703","volume":"11","author":"BN Callahan","year":"2020","unstructured":"Callahan BN, et al. Osthole, a natural plant derivative inhibits MRGPRX2 induced mast cell responses. Front Immunol. 2020;11:703.","journal-title":"Front Immunol"},{"issue":"5","key":"2144_CR20","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.immuni.2019.03.013","volume":"50","author":"J Meixiong","year":"2019","unstructured":"Meixiong J, et al. Activation of mast-cell-expressed mas-related G-protein-coupled receptors drives non-histaminergic itch. Immunity. 2019;50(5):1163\u201371. e5.","journal-title":"Immunity"},{"issue":"7","key":"2144_CR21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH image to imageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671\u20135.","journal-title":"Nat Methods"},{"issue":"12","key":"2144_CR22","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/exd.12030","volume":"21","author":"C Casas","year":"2012","unstructured":"Casas C, et al. Quantification of demodex folliculorum by PCR in rosacea and its relationship to skin innate immune activation. Exp Dermatol. 2012;21(12):906\u201310.","journal-title":"Exp Dermatol"},{"issue":"1","key":"2144_CR23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jid.2023.06.201","volume":"144","author":"T Jia","year":"2024","unstructured":"Jia T, et al. Mast cells initiate type 2 inflammation through tryptase released by MRGPRX2\/MRGPRB2 activation in atopic dermatitis. J Invest Dermatol. 2024;144(1):53\u201362. e2.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"2144_CR24","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/cei.13575","volume":"204","author":"P Chieosilapatham","year":"2021","unstructured":"Chieosilapatham P, et al. Keratinocytes: innate immune cells in atopic dermatitis. Clin Experimental Immunol. 2021;204(3):296\u2013309.","journal-title":"Clin Experimental Immunol"},{"key":"2144_CR25","doi-asserted-by":"crossref","first-page":"1211953","DOI":"10.3389\/fimmu.2023.1211953","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. The role of macrophages in rosacea: implications for targeted therapies. Front Immunol. 2023;14:1211953.","journal-title":"Front Immunol"},{"issue":"4","key":"2144_CR26","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/jdv.18725","volume":"37","author":"L Zhou","year":"2023","unstructured":"Zhou L, et al. GBP5 exacerbates rosacea-like skin inflammation by skewing macrophage polarization towards M1 phenotype through the NF\u2010\u03baB signalling pathway. J Eur Acad Dermatol Venereol. 2023;37(4):796\u2013809.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2144_CR27","doi-asserted-by":"crossref","first-page":"1285951","DOI":"10.3389\/fimmu.2023.1285951","volume":"14","author":"S Tang","year":"2024","unstructured":"Tang S, et al. OPN promotes pro-inflammatory cytokine expression via ERK\/JNK pathway and M1 macrophage polarization in rosacea. Front Immunol. 2024;14:1285951.","journal-title":"Front Immunol"},{"issue":"52","key":"2144_CR28","doi-asserted-by":"crossref","first-page":"44739","DOI":"10.1074\/jbc.M111.277152","volume":"286","author":"H Subramanian","year":"2011","unstructured":"Subramanian H, et al. Mas-related gene X2 (MrgX2) is a novel G protein-coupled receptor for the antimicrobial peptide LL-37 in human mast cells: resistance to receptor phosphorylation, desensitization, and internalization. J Biol Chem. 2011;286(52):44739\u201349.","journal-title":"J Biol Chem"},{"key":"2144_CR29","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s004030050189","volume":"289","author":"TE Damsgaard","year":"1997","unstructured":"Damsgaard TE, et al. Mast cells and atopic dermatitis. Stereological quantification of mast cells in atopic dermatitis and normal human skin. Arch Dermatol Res. 1997;289:256\u201360.","journal-title":"Arch Dermatol Res"},{"key":"2144_CR30","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s004030050317","volume":"290","author":"L Ackermann","year":"1998","unstructured":"Ackermann L, Harvima I. Mast cells of psoriatic and atopic dermatitis skin are positive for TNF-\u03b1 and their degranulation is associated with expression of ICAM-1 in the epidermis. Arch Dermatol Res. 1998;290:353\u20139.","journal-title":"Arch Dermatol Res"},{"key":"2144_CR31","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00403-002-0378-z","volume":"295","author":"A J\u00e4rvikallio","year":"2003","unstructured":"J\u00e4rvikallio A, Harvima IT, Naukkarinen A. Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema. Arch Dermatol Res. 2003;295:2\u20137.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"2144_CR32","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12016-011-8252-4","volume":"41","author":"FT Liu","year":"2011","unstructured":"Liu FT, Goodarzi H, Chen HY. IgE, mast cells, and eosinophils in atopic dermatitis. Clin Rev Allergy Immunol. 2011;41(3):298\u2013310.","journal-title":"Clin Rev Allergy Immunol"},{"key":"2144_CR33","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3389\/fmed.2019.00324","volume":"6","author":"L Wang","year":"2020","unstructured":"Wang L, et al. The theranostics role of mast cells in the pathophysiology of rosacea. Front Med. 2020;6:324.","journal-title":"Front Med"},{"issue":"8","key":"2144_CR34","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/exd.13143","volume":"26","author":"AD Holmes","year":"2017","unstructured":"Holmes AD, Steinhoff M. Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics. Exp Dermatol. 2017;26(8):659\u201367.","journal-title":"Exp Dermatol"},{"issue":"4","key":"2144_CR35","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/1521-4141(200104)31:4<1066::AID-IMMU1066>3.0.CO;2-#","volume":"31","author":"F Niyonsaba","year":"2001","unstructured":"Niyonsaba F, et al. Evaluation of the effects of peptide antibiotics human \u03b2-defensins\u20101\/\u20102 and LL\u201037 on Histamine release and prostaglandin D2 production from mast cells. Eur J Immunol. 2001;31(4):1066\u201375.","journal-title":"Eur J Immunol"},{"issue":"7","key":"2144_CR36","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.4049\/jimmunol.0900712","volume":"184","author":"F Niyonsaba","year":"2010","unstructured":"Niyonsaba F, et al. Antimicrobial peptides human \u03b2-defensins and Cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells. J Immunol. 2010;184(7):3526\u201334.","journal-title":"J Immunol"},{"issue":"4","key":"2144_CR37","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/IOP.0b013e31824dd9d4","volume":"28","author":"EJ Wladis","year":"2012","unstructured":"Wladis EJ, et al. Molecular biologic assessment of cutaneous specimens of ocular rosacea. Ophthalmic Plast Reconstr Surg. 2012;28(4):246\u201350.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"2144_CR38","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1016\/S0151-9638(11)70088-6","volume":"138","author":"B Cribier","year":"2011","unstructured":"Cribier B. Pathophysiology of rosacea: redness, telangiectasia, and rosacea. Ann Derm V\u00e9n\u00e9r\u00e9ologie. 2011;138:S184.","journal-title":"Ann Derm V\u00e9n\u00e9r\u00e9ologie"},{"issue":"10","key":"2144_CR39","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.jid.2020.02.025","volume":"140","author":"B Medgyesi","year":"2020","unstructured":"Medgyesi B, et al. Rosacea is characterized by a profoundly diminished skin barrier. J Invest Dermatol. 2020;140(10):1938\u201350. e5.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"2144_CR40","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/exd.14182","volume":"29","author":"Z Wang","year":"2020","unstructured":"Wang Z, Babina M. MRGPRX2 signals its importance in cutaneous mast cell biology: does MRGPRX2 connect mast cells and atopic dermatitis? Exp Dermatol. 2020;29(11):1104\u201311.","journal-title":"Exp Dermatol"},{"key":"2144_CR41","doi-asserted-by":"crossref","first-page":"492189","DOI":"10.3389\/fimmu.2019.03143","volume":"10","author":"CJ Occhiuto","year":"2020","unstructured":"Occhiuto CJ, et al. Store-operated calcium entry via STIM1 contributes to MRGPRX2 induced mast cell functions. Front Immunol. 2020;10:492189.","journal-title":"Front Immunol"},{"key":"2144_CR42","doi-asserted-by":"crossref","first-page":"674871","DOI":"10.3389\/fimmu.2021.674871","volume":"12","author":"Z Deng","year":"2021","unstructured":"Deng Z, et al. Keratinocyte-immune cell crosstalk in a STAT1-mediated pathway: novel insights into rosacea pathogenesis. Front Immunol. 2021;12:674871.","journal-title":"Front Immunol"},{"issue":"4","key":"2144_CR43","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/1346-8138.14774","volume":"46","author":"T Hara","year":"2019","unstructured":"Hara T, et al. Peripheral blood eosinophilia is associated with the presence of skin ulcers in patients with systemic sclerosis. J Dermatol. 2019;46(4):334\u20137.","journal-title":"J Dermatol"},{"issue":"4","key":"2144_CR44","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jid.2020.08.013","volume":"141","author":"JL Harden","year":"2021","unstructured":"Harden JL, et al. Paired transcriptomic and proteomic analysis implicates IL-1\u03b2 in the pathogenesis of papulopustular rosacea explants. J Invest Dermatol. 2021;141(4):800\u20139.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"2144_CR45","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/exd.13702","volume":"27","author":"E Suhng","year":"2018","unstructured":"Suhng E, et al. Increased expression of IL-33 in rosacea skin and UVB\u2010irradiated and LL\u201037\u2010treated HaCaT cells. Exp Dermatol. 2018;27(9):1023\u20139.","journal-title":"Exp Dermatol"},{"issue":"5","key":"2144_CR46","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.jid.2019.09.021","volume":"140","author":"Y-H Shih","year":"2020","unstructured":"Shih Y-H, et al. Alterations of immune and keratinization gene expression in papulopustular rosacea by whole transcriptome analysis. J Invest Dermatol. 2020;140(5):1100\u20133. e4.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2144_CR47","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/cells10010102","volume":"10","author":"M Babina","year":"2021","unstructured":"Babina M, et al. Thymic stromal lymphopoietin promotes MRGPRX2-triggered degranulation of skin mast cells in a STAT5-dependent manner with further support from JNK. Cells. 2021;10(1):102.","journal-title":"Cells"},{"issue":"11","key":"2144_CR48","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/j.jid.2018.05.008","volume":"138","author":"T Gao","year":"2018","unstructured":"Gao T, et al. The neuropeptide Y system regulates both mechanical and histaminergic itch. J Invest Dermatol. 2018;138(11):2405\u201311.","journal-title":"J Invest Dermatol"},{"issue":"16","key":"2144_CR49","doi-asserted-by":"crossref","first-page":"e89362","DOI":"10.1172\/jci.insight.89362","volume":"1","author":"E Azimi","year":"2016","unstructured":"Azimi E et al. Dual action of neurokinin-1 antagonists on Mas-related GPCRs. JCI Insight, 2016;1(16):e89362.","journal-title":"JCI insight"},{"issue":"16","key":"2144_CR50","doi-asserted-by":"crossref","first-page":"e89362","DOI":"10.1172\/jci.insight.89362","volume":"1","author":"E Azimi","year":"2016","unstructured":"Azimi E, et al. Dual action of neurokinin-1 antagonists on Mas-related GPCRs. JCI Insight. 2016;1(16):e89362.","journal-title":"JCI Insight"},{"issue":"3","key":"2144_CR51","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/jdv.20249","volume":"39","author":"M Kumar","year":"2025","unstructured":"Kumar M, et al. Beyond the classic players: mas-related G protein\u2010coupled receptor member X2 role in pruritus and skin diseases. J Eur Acad Dermatol Venereol. 2025;39(3):476\u201386.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"2144_CR52","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.3390\/ijms23052684","volume":"23","author":"L Fania","year":"2022","unstructured":"Fania L, et al. Multiple roles for cytokines in atopic dermatitis: from pathogenic mediators to endotype-specific biomarkers to therapeutic targets. Int J Mol Sci. 2022;23(5):2684.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2144_CR53","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.4049\/jimmunol.178.6.3373","volume":"178","author":"SI Bogiatzi","year":"2007","unstructured":"Bogiatzi SI, et al. Cutting edge: proinflammatory and Th2 cytokines synergize to induce thymic stromal lymphopoietin production by human skin keratinocytes. J Immunol. 2007;178(6):3373\u20137.","journal-title":"J Immunol"},{"issue":"5","key":"2144_CR54","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/jid.2011.446","volume":"132","author":"T Savinko","year":"2012","unstructured":"Savinko T, et al. IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J Invest Dermatol. 2012;132(5):1392\u2013400.","journal-title":"J Invest Dermatol"},{"issue":"7","key":"2144_CR55","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3390\/cells10071615","volume":"10","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Kurashima Y. Two sides of the coin: mast cells as a key regulator of allergy and acute\/chronic inflammation. Cells. 2021;10(7):1615.","journal-title":"Cells"},{"issue":"170","key":"2144_CR56","first-page":"ra17016","volume":"5","author":"BS Kim","year":"2013","unstructured":"Kim BS, et al. TSLP elicits IL-33\u2013independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med. 2013;5(170):ra17016\u201317016.","journal-title":"Sci Transl Med"},{"issue":"2","key":"2144_CR57","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.alit.2020.01.001","volume":"69","author":"S Nakajima","year":"2020","unstructured":"Nakajima S, et al. Anti-TSLP antibodies: targeting a master regulator of type 2 immune responses. Allergology Int. 2020;69(2):197\u2013203.","journal-title":"Allergology Int"},{"issue":"4","key":"2144_CR58","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/1346-8138.14792","volume":"46","author":"Z Deng","year":"2019","unstructured":"Deng Z, et al. Claudin reduction may relate to an impaired skin barrier in rosacea. J Dermatol. 2019;46(4):314\u201321.","journal-title":"J Dermatol"},{"key":"2144_CR59","doi-asserted-by":"crossref","first-page":"1406438","DOI":"10.3389\/fimmu.2024.1406438","volume":"15","author":"TK Wong","year":"2024","unstructured":"Wong TK, et al. MRGPRX2 antagonist GE1111 attenuated DNFB-induced atopic dermatitis in mice by reducing inflammatory cytokines and restoring skin integrity. Front Immunol. 2024;15:1406438.","journal-title":"Front Immunol"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-025-02144-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-025-02144-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-025-02144-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T16:54:18Z","timestamp":1767200058000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-025-02144-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2144"],"URL":"https:\/\/doi.org\/10.1007\/s00011-025-02144-y","relation":{},"ISSN":["1023-3830","1420-908X"],"issn-type":[{"value":"1023-3830","type":"print"},{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to update on Funding section.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"174"}}